In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Things Are Looking Up On The US Regulatory/Policy Front

Executive Summary

Going in to 2016, it's hard not to characterize the US regulatory and policy environment as positive for the medical device industry. There is a consensus that the FDA premarket review process in 2015 has become, on average, more efficient and more transparent that it was five to 10 years ago. And policymakers, if anything, are focused on furthering that trend.

Advertisement

Related Content

2016 Will Be A Big Year For Combo Product Reform, FDA Says
Breakthrough Reimbursement Proposals Percolate From FDA, Industry
'Cures' Bill Passes, As More Budget, Safety Debates Wait In The Wings

Topics

UsernamePublicRestriction

Register

IV004452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel